Syros Pharmaceuticals (SYRS) and Fortress Biotech (FBIO) Critical Analysis
Syros Pharmaceuticals (NASDAQ: SYRS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Volatility & Risk
Syros Pharmaceuticals has a beta of -2.26, indicating that its stock price is 326% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
48.8% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 11.9% of Fortress Biotech shares are held by institutional investors. 33.6% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 33.3% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Syros Pharmaceuticals and Fortress Biotech’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Syros Pharmaceuticals||$320,000.00||1,051.20||-$47.74 million||($2.01)||-5.20|
|Fortress Biotech||$16.48 million||13.03||-$55.09 million||($1.83)||-2.32|
Syros Pharmaceuticals has higher earnings, but lower revenue than Fortress Biotech. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
This table compares Syros Pharmaceuticals and Fortress Biotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Syros Pharmaceuticals and Fortress Biotech, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Syros Pharmaceuticals currently has a consensus price target of $23.83, suggesting a potential upside of 128.08%. Fortress Biotech has a consensus price target of $10.80, suggesting a potential upside of 154.72%. Given Fortress Biotech’s stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Syros Pharmaceuticals.
Fortress Biotech beats Syros Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
About Fortress Biotech
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.